
Journal of Medicinal Chemistry p. 625 - 629 (1994)
Update date:2022-07-29
Topics:
Thurieau, Christophe
Simonet, Serge
Paladino, Joseph
Prost, Jean-Francois
Verbeuren, Tony
Fauchere, Jean-Luc
We report on the synthesis and pharmacological properties of a new series of thrombin inhibitors derived from hirudin carboxyl-terminal fragments.Two (arylphosphono)phenylalanines, p-PO3H2-L-Phe1 and m-PO3H2-L-Tyr, and one (carboxymethyl)phenylalanine, p-CH2COOH-L-Phe, were prepared and incorporated into position 63 of the modified hirudin's C-terminal dodecapeptide using the Fmoc solid-phase synthesis strategy.Substitution by any one of the residues led to very active analogs which doubled the thrombin time at low micromolar concentration (Ctt2) in vitro (1 μM < Ctt2 < 3 μM) and potently increased the activated partial thromboplastin time (APTT) ex vivo.These compounds displayed a higher potency in vitro and a longer duration of action in vivo than both the corresponding sulfated or phosphorylated tyrosine counterparts.
View MoreZhonghao (dalian) Research and Design Institute of Chemical Industry Co., Ltd
Contact:+86 411 84674606
Address:201, Huangpu Road , Shahekou District, Dalian ,116023-China
Weifang Arylchem Chemical Co., LTD
Contact:86-536-5217866
Address:Development Zone, Shouguang, Shandong Province
Jiangsu Cale New Material Co.ltd
Contact:+86-515-88334667/88203550
Address:Zhongshan 3rd Road, Coastal Chemical Industry Park, Yancheng, Jiangsu, China
Contact:+91 - 22 - 26355700
Address:17, Lotus Business Park, Andheri West
Contact:+65 9658 0999
Address:26 Sin Ming Lane, Midview City, #05-118, Singapore 573971
Doi:10.1016/S0040-4039(00)61619-2
(1993)Doi:10.1002/ejoc.201900450
(2019)Doi:10.1039/C6CC09323J
(2017)Doi:10.1002/hlca.19940770213
(1994)Doi:10.1080/15257779508012405
(1995)Doi:10.1016/0045-6535(94)90008-6
(1994)